Know Cancer

or
forgot password

Early Response Assessment in Patients With Diffuse Large B-cell Lymphoma Using 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)


N/A
18 Years
N/A
Open (Enrolling)
Both
Diffuse Large B-cell Lymphoma

Thank you

Trial Information

Early Response Assessment in Patients With Diffuse Large B-cell Lymphoma Using 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)


Inclusion Criteria:



- Patients must have histologically or cytologically confirmed diagnosis of CD20+
diffuse large B cell lymphoma (LBCL) of any stage, including subtypes mediastinal
large B cell, centroblastic, immunoblastic, T cell rich B cell and anaplastic B cell
lymphoma

- Patients must have received no prior anti-lymphoma therapy.

- Age >18 years.

- Patients must have a treatment plan to include R/CHOP or R/CHOP followed by
radiotherapy.

- Ability to understand and the willingness to sign a written informed consent
document.

Exclusion Criteria:

- Patients who have known HIV infection.

- Patients who are, in the opinion of their treating oncologist, unable to undergo
R/CHOP chemotherapy.

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

evaluating the predictive value of a positive PET scan early in the course of standard chemotherapy

Outcome Time Frame:

after 2 cycles of chemotherapy

Safety Issue:

No

Principal Investigator

Rebecca Elstrom, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Weill Medical College of Cornell University

Authority:

United States: Institutional Review Board

Study ID:

0801009588

NCT ID:

NCT00754117

Start Date:

May 2008

Completion Date:

Related Keywords:

  • Diffuse Large B-Cell Lymphoma
  • diffuse large b cell lymphoma
  • newly diagnosed
  • Lymphoma
  • Lymphoma, B-Cell
  • Lymphoma, Large B-Cell, Diffuse

Name

Location

Weill Cornell Medical CollegeNew York, New York  10021